Open AccessVitamin D and Vitamin D Analogs as Cancer Chemopreventive Agents
Author(s) -
Guyton Kathryn Z.,
Kensler Thomas W.,
Posner Gary H.
Publication year - 2003
Publication title -
nutrition reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.958
H-Index - 150
eISSN - 1753-4887
pISSN - 0029-6643
DOI - 10.1301/nr.2003.jul.227-238
Subject(s) - vitamin d and neurology , calcitriol receptor , vitamin , cancer , prostate cancer , breast cancer , medicine , cancer prevention , angiogenesis , endocrinology , limiting , cancer research , pharmacology , mechanical engineering , engineering
Epidemiologic studies have associated vitamin D, attained through nutrition and sun exposure, with reduced cancer risk. Although dose‐limiting hypercalcemia has limited the use of natural vitamin D in cancer prevention, several promising new synthetic vitamin D analogs (deltanoids) are under development. Examples are KH‐1060, EB1089, 1 α ‐hydroxyvitamin D 5 , vitamin D 2 , and QW‐1624F2‐2. Clinical targets for deltanoids include colon, prostate, and breast. Studies to elucidate the molecular mechanisms underlying the observed efficacy of deltanoids are ongoing. The vitamin D receptor, a steroid/thyroid receptor superfamily member, appears to control most deltanoid effects on proliferation, apoptosis, differentiation, and angiogenesis.